nodes	percent_of_prediction	percent_of_DWPC	metapath
Paliperidone—CYP3A5—Paclitaxel—ovarian cancer	0.0466	0.194	CbGbCtD
Paliperidone—CYP2D6—Vinorelbine—ovarian cancer	0.0407	0.169	CbGbCtD
Paliperidone—CYP3A4—Topotecan—ovarian cancer	0.0367	0.153	CbGbCtD
Paliperidone—CYP3A5—Docetaxel—ovarian cancer	0.0337	0.14	CbGbCtD
Paliperidone—CYP3A4—Vinorelbine—ovarian cancer	0.0259	0.108	CbGbCtD
Paliperidone—CYP3A4—Paclitaxel—ovarian cancer	0.0182	0.0757	CbGbCtD
Paliperidone—CYP2D6—Doxorubicin—ovarian cancer	0.0154	0.0641	CbGbCtD
Paliperidone—CYP3A4—Docetaxel—ovarian cancer	0.0131	0.0547	CbGbCtD
Paliperidone—CYP3A4—Doxorubicin—ovarian cancer	0.0098	0.0408	CbGbCtD
Paliperidone—HTR2A—vein—ovarian cancer	0.0057	0.111	CbGeAlD
Paliperidone—DRD4—testis—ovarian cancer	0.00269	0.0526	CbGeAlD
Paliperidone—ADRA2C—myometrium—ovarian cancer	0.00165	0.0323	CbGeAlD
Paliperidone—ADRA1A—epithelium—ovarian cancer	0.00136	0.0266	CbGeAlD
Paliperidone—HTR1B—female reproductive system—ovarian cancer	0.00136	0.0266	CbGeAlD
Paliperidone—HRH1—myometrium—ovarian cancer	0.00134	0.0263	CbGeAlD
Paliperidone—ADRA2A—myometrium—ovarian cancer	0.00132	0.0258	CbGeAlD
Paliperidone—HTR1D—female reproductive system—ovarian cancer	0.00132	0.0257	CbGeAlD
Paliperidone—HTR2C—female reproductive system—ovarian cancer	0.0013	0.0255	CbGeAlD
Paliperidone—ADRA2C—uterine cervix—ovarian cancer	0.00129	0.0252	CbGeAlD
Paliperidone—ADRA2C—decidua—ovarian cancer	0.00123	0.024	CbGeAlD
Paliperidone—ADRA2C—endometrium—ovarian cancer	0.00116	0.0228	CbGeAlD
Paliperidone—HTR2A—embryo—ovarian cancer	0.00108	0.0211	CbGeAlD
Paliperidone—CYP3A5—uterine cervix—ovarian cancer	0.00108	0.0211	CbGeAlD
Paliperidone—ADRA2C—uterus—ovarian cancer	0.00107	0.021	CbGeAlD
Paliperidone—HRH1—epithelium—ovarian cancer	0.00105	0.0206	CbGeAlD
Paliperidone—HRH1—uterine cervix—ovarian cancer	0.00104	0.0204	CbGeAlD
Paliperidone—ADRA2A—uterine cervix—ovarian cancer	0.00103	0.0201	CbGeAlD
Paliperidone—HRH1—decidua—ovarian cancer	0.000996	0.0195	CbGeAlD
Paliperidone—ADRA2A—decidua—ovarian cancer	0.000978	0.0191	CbGeAlD
Paliperidone—HRH1—endometrium—ovarian cancer	0.000945	0.0185	CbGeAlD
Paliperidone—ADRA2A—endometrium—ovarian cancer	0.000928	0.0182	CbGeAlD
Paliperidone—HTR2A—epithelium—ovarian cancer	0.00088	0.0172	CbGeAlD
Paliperidone—ADRA2C—female gonad—ovarian cancer	0.000877	0.0172	CbGeAlD
Paliperidone—ADRA2C—vagina—ovarian cancer	0.000872	0.0171	CbGeAlD
Paliperidone—ADRA2A—gonad—ovarian cancer	0.000861	0.0168	CbGeAlD
Paliperidone—ADRA2A—uterus—ovarian cancer	0.000855	0.0167	CbGeAlD
Paliperidone—DRD2—testis—ovarian cancer	0.0008	0.0157	CbGeAlD
Paliperidone—HRH1—female reproductive system—ovarian cancer	0.000783	0.0153	CbGeAlD
Paliperidone—ADRA2C—testis—ovarian cancer	0.000778	0.0152	CbGeAlD
Paliperidone—ADRA2A—female reproductive system—ovarian cancer	0.000769	0.015	CbGeAlD
Paliperidone—CYP3A5—female gonad—ovarian cancer	0.000734	0.0144	CbGeAlD
Paliperidone—HTR2A—gonad—ovarian cancer	0.000732	0.0143	CbGeAlD
Paliperidone—CYP3A5—vagina—ovarian cancer	0.00073	0.0143	CbGeAlD
Paliperidone—HRH1—female gonad—ovarian cancer	0.000712	0.0139	CbGeAlD
Paliperidone—HRH1—vagina—ovarian cancer	0.000708	0.0139	CbGeAlD
Paliperidone—ADRA2A—female gonad—ovarian cancer	0.0007	0.0137	CbGeAlD
Paliperidone—ADRA2A—vagina—ovarian cancer	0.000696	0.0136	CbGeAlD
Paliperidone—HTR2A—female reproductive system—ovarian cancer	0.000654	0.0128	CbGeAlD
Paliperidone—HRH1—testis—ovarian cancer	0.000632	0.0124	CbGeAlD
Paliperidone—ADRA2A—testis—ovarian cancer	0.000621	0.0121	CbGeAlD
Paliperidone—CYP3A4—female reproductive system—ovarian cancer	0.000605	0.0118	CbGeAlD
Paliperidone—CYP2D6—female reproductive system—ovarian cancer	0.000596	0.0117	CbGeAlD
Paliperidone—HTR2A—vagina—ovarian cancer	0.000591	0.0116	CbGeAlD
Paliperidone—ADRA2C—lymph node—ovarian cancer	0.000564	0.011	CbGeAlD
Paliperidone—CYP2D6—female gonad—ovarian cancer	0.000542	0.0106	CbGeAlD
Paliperidone—HTR2A—testis—ovarian cancer	0.000528	0.0103	CbGeAlD
Paliperidone—CYP2D6—testis—ovarian cancer	0.000481	0.0094	CbGeAlD
Paliperidone—HRH1—lymph node—ovarian cancer	0.000458	0.00896	CbGeAlD
Paliperidone—ADRA2A—lymph node—ovarian cancer	0.00045	0.0088	CbGeAlD
Paliperidone—Arthralgia—Docetaxel—ovarian cancer	0.000394	0.000565	CcSEcCtD
Paliperidone—Myalgia—Docetaxel—ovarian cancer	0.000394	0.000565	CcSEcCtD
Paliperidone—Nausea—Vinorelbine—ovarian cancer	0.000394	0.000565	CcSEcCtD
Paliperidone—Dyspepsia—Paclitaxel—ovarian cancer	0.000392	0.000563	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—ovarian cancer	0.000391	0.000561	CcSEcCtD
Paliperidone—Jaundice—Epirubicin—ovarian cancer	0.000389	0.000559	CcSEcCtD
Paliperidone—Urinary tract infection—Epirubicin—ovarian cancer	0.000388	0.000557	CcSEcCtD
Paliperidone—Conjunctivitis—Epirubicin—ovarian cancer	0.000388	0.000557	CcSEcCtD
Paliperidone—Dysuria—Doxorubicin—ovarian cancer	0.000388	0.000556	CcSEcCtD
Paliperidone—Neutropenia—Doxorubicin—ovarian cancer	0.000388	0.000556	CcSEcCtD
Paliperidone—Decreased appetite—Paclitaxel—ovarian cancer	0.000388	0.000556	CcSEcCtD
Paliperidone—Dry mouth—Docetaxel—ovarian cancer	0.000385	0.000553	CcSEcCtD
Paliperidone—Upper respiratory tract infection—Doxorubicin—ovarian cancer	0.000385	0.000553	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.000385	0.000552	CcSEcCtD
Paliperidone—Fatigue—Paclitaxel—ovarian cancer	0.000384	0.000551	CcSEcCtD
Paliperidone—Pollakiuria—Doxorubicin—ovarian cancer	0.000383	0.000549	CcSEcCtD
Paliperidone—Pain—Paclitaxel—ovarian cancer	0.000381	0.000547	CcSEcCtD
Paliperidone—Constipation—Paclitaxel—ovarian cancer	0.000381	0.000547	CcSEcCtD
Paliperidone—Confusional state—Docetaxel—ovarian cancer	0.000381	0.000546	CcSEcCtD
Paliperidone—Hepatobiliary disease—Epirubicin—ovarian cancer	0.000378	0.000542	CcSEcCtD
Paliperidone—Anaphylactic shock—Docetaxel—ovarian cancer	0.000378	0.000542	CcSEcCtD
Paliperidone—Oedema—Docetaxel—ovarian cancer	0.000378	0.000542	CcSEcCtD
Paliperidone—Weight increased—Doxorubicin—ovarian cancer	0.000377	0.000541	CcSEcCtD
Paliperidone—Epistaxis—Epirubicin—ovarian cancer	0.000377	0.000541	CcSEcCtD
Paliperidone—Infection—Docetaxel—ovarian cancer	0.000375	0.000538	CcSEcCtD
Paliperidone—Weight decreased—Doxorubicin—ovarian cancer	0.000375	0.000538	CcSEcCtD
Paliperidone—Sinusitis—Epirubicin—ovarian cancer	0.000375	0.000538	CcSEcCtD
Paliperidone—Hyperglycaemia—Doxorubicin—ovarian cancer	0.000374	0.000537	CcSEcCtD
Paliperidone—Agranulocytosis—Epirubicin—ovarian cancer	0.000373	0.000535	CcSEcCtD
Paliperidone—Pneumonia—Doxorubicin—ovarian cancer	0.000372	0.000533	CcSEcCtD
Paliperidone—Shock—Docetaxel—ovarian cancer	0.000372	0.000533	CcSEcCtD
Paliperidone—Nervous system disorder—Docetaxel—ovarian cancer	0.000371	0.000531	CcSEcCtD
Paliperidone—Thrombocytopenia—Docetaxel—ovarian cancer	0.00037	0.000531	CcSEcCtD
Paliperidone—Infestation NOS—Doxorubicin—ovarian cancer	0.00037	0.00053	CcSEcCtD
Paliperidone—Infestation—Doxorubicin—ovarian cancer	0.00037	0.00053	CcSEcCtD
Paliperidone—Tachycardia—Docetaxel—ovarian cancer	0.000369	0.000529	CcSEcCtD
Paliperidone—Feeling abnormal—Paclitaxel—ovarian cancer	0.000367	0.000527	CcSEcCtD
Paliperidone—Skin disorder—Docetaxel—ovarian cancer	0.000367	0.000526	CcSEcCtD
Paliperidone—Bradycardia—Epirubicin—ovarian cancer	0.000365	0.000524	CcSEcCtD
Paliperidone—Gastrointestinal pain—Paclitaxel—ovarian cancer	0.000365	0.000523	CcSEcCtD
Paliperidone—Jaundice—Doxorubicin—ovarian cancer	0.00036	0.000517	CcSEcCtD
Paliperidone—Anorexia—Docetaxel—ovarian cancer	0.00036	0.000517	CcSEcCtD
Paliperidone—Rhinitis—Epirubicin—ovarian cancer	0.00036	0.000516	CcSEcCtD
Paliperidone—Urinary tract infection—Doxorubicin—ovarian cancer	0.000359	0.000516	CcSEcCtD
Paliperidone—Conjunctivitis—Doxorubicin—ovarian cancer	0.000359	0.000516	CcSEcCtD
Paliperidone—Hypoaesthesia—Epirubicin—ovarian cancer	0.000357	0.000512	CcSEcCtD
Paliperidone—Urinary tract disorder—Epirubicin—ovarian cancer	0.000354	0.000508	CcSEcCtD
Paliperidone—Urticaria—Paclitaxel—ovarian cancer	0.000354	0.000508	CcSEcCtD
Paliperidone—Oedema peripheral—Epirubicin—ovarian cancer	0.000353	0.000507	CcSEcCtD
Paliperidone—Hypotension—Docetaxel—ovarian cancer	0.000353	0.000506	CcSEcCtD
Paliperidone—Connective tissue disorder—Epirubicin—ovarian cancer	0.000352	0.000506	CcSEcCtD
Paliperidone—Abdominal pain—Paclitaxel—ovarian cancer	0.000352	0.000505	CcSEcCtD
Paliperidone—Body temperature increased—Paclitaxel—ovarian cancer	0.000352	0.000505	CcSEcCtD
Paliperidone—Urethral disorder—Epirubicin—ovarian cancer	0.000352	0.000504	CcSEcCtD
Paliperidone—Hepatobiliary disease—Doxorubicin—ovarian cancer	0.00035	0.000502	CcSEcCtD
Paliperidone—Epistaxis—Doxorubicin—ovarian cancer	0.000349	0.0005	CcSEcCtD
Paliperidone—Sinusitis—Doxorubicin—ovarian cancer	0.000347	0.000498	CcSEcCtD
Paliperidone—Agranulocytosis—Doxorubicin—ovarian cancer	0.000345	0.000495	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Docetaxel—ovarian cancer	0.000344	0.000494	CcSEcCtD
Paliperidone—Insomnia—Docetaxel—ovarian cancer	0.000342	0.00049	CcSEcCtD
Paliperidone—Paraesthesia—Docetaxel—ovarian cancer	0.000339	0.000487	CcSEcCtD
Paliperidone—Bradycardia—Doxorubicin—ovarian cancer	0.000338	0.000485	CcSEcCtD
Paliperidone—Dyspnoea—Docetaxel—ovarian cancer	0.000337	0.000483	CcSEcCtD
Paliperidone—Somnolence—Docetaxel—ovarian cancer	0.000336	0.000482	CcSEcCtD
Paliperidone—Eye disorder—Epirubicin—ovarian cancer	0.000335	0.000481	CcSEcCtD
Paliperidone—Tinnitus—Epirubicin—ovarian cancer	0.000334	0.00048	CcSEcCtD
Paliperidone—Flushing—Epirubicin—ovarian cancer	0.000333	0.000478	CcSEcCtD
Paliperidone—Cardiac disorder—Epirubicin—ovarian cancer	0.000333	0.000478	CcSEcCtD
Paliperidone—Rhinitis—Doxorubicin—ovarian cancer	0.000333	0.000477	CcSEcCtD
Paliperidone—Dyspepsia—Docetaxel—ovarian cancer	0.000333	0.000477	CcSEcCtD
Paliperidone—Hypoaesthesia—Doxorubicin—ovarian cancer	0.00033	0.000474	CcSEcCtD
Paliperidone—Decreased appetite—Docetaxel—ovarian cancer	0.000328	0.000471	CcSEcCtD
Paliperidone—Hypersensitivity—Paclitaxel—ovarian cancer	0.000328	0.000471	CcSEcCtD
Paliperidone—Urinary tract disorder—Doxorubicin—ovarian cancer	0.000328	0.00047	CcSEcCtD
Paliperidone—Oedema peripheral—Doxorubicin—ovarian cancer	0.000327	0.000469	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.000326	0.000468	CcSEcCtD
Paliperidone—Connective tissue disorder—Doxorubicin—ovarian cancer	0.000326	0.000468	CcSEcCtD
Paliperidone—Fatigue—Docetaxel—ovarian cancer	0.000326	0.000467	CcSEcCtD
Paliperidone—Angiopathy—Epirubicin—ovarian cancer	0.000325	0.000467	CcSEcCtD
Paliperidone—Urethral disorder—Doxorubicin—ovarian cancer	0.000325	0.000467	CcSEcCtD
Paliperidone—Immune system disorder—Epirubicin—ovarian cancer	0.000324	0.000465	CcSEcCtD
Paliperidone—Mediastinal disorder—Epirubicin—ovarian cancer	0.000323	0.000464	CcSEcCtD
Paliperidone—Constipation—Docetaxel—ovarian cancer	0.000323	0.000463	CcSEcCtD
Paliperidone—Pain—Docetaxel—ovarian cancer	0.000323	0.000463	CcSEcCtD
Paliperidone—Chills—Epirubicin—ovarian cancer	0.000322	0.000462	CcSEcCtD
Paliperidone—Asthenia—Paclitaxel—ovarian cancer	0.00032	0.000459	CcSEcCtD
Paliperidone—Alopecia—Epirubicin—ovarian cancer	0.000317	0.000455	CcSEcCtD
Paliperidone—Pruritus—Paclitaxel—ovarian cancer	0.000315	0.000452	CcSEcCtD
Paliperidone—Mental disorder—Epirubicin—ovarian cancer	0.000314	0.000451	CcSEcCtD
Paliperidone—Malnutrition—Epirubicin—ovarian cancer	0.000312	0.000448	CcSEcCtD
Paliperidone—Erythema—Epirubicin—ovarian cancer	0.000312	0.000448	CcSEcCtD
Paliperidone—Feeling abnormal—Docetaxel—ovarian cancer	0.000311	0.000447	CcSEcCtD
Paliperidone—Eye disorder—Doxorubicin—ovarian cancer	0.00031	0.000445	CcSEcCtD
Paliperidone—Tinnitus—Doxorubicin—ovarian cancer	0.000309	0.000444	CcSEcCtD
Paliperidone—Gastrointestinal pain—Docetaxel—ovarian cancer	0.000309	0.000443	CcSEcCtD
Paliperidone—Flushing—Doxorubicin—ovarian cancer	0.000308	0.000442	CcSEcCtD
Paliperidone—Cardiac disorder—Doxorubicin—ovarian cancer	0.000308	0.000442	CcSEcCtD
Paliperidone—Flatulence—Epirubicin—ovarian cancer	0.000308	0.000441	CcSEcCtD
Paliperidone—Tension—Epirubicin—ovarian cancer	0.000306	0.00044	CcSEcCtD
Paliperidone—Dysgeusia—Epirubicin—ovarian cancer	0.000306	0.000439	CcSEcCtD
Paliperidone—Diarrhoea—Paclitaxel—ovarian cancer	0.000305	0.000437	CcSEcCtD
Paliperidone—Nervousness—Epirubicin—ovarian cancer	0.000303	0.000435	CcSEcCtD
Paliperidone—Back pain—Epirubicin—ovarian cancer	0.000302	0.000433	CcSEcCtD
Paliperidone—Angiopathy—Doxorubicin—ovarian cancer	0.000301	0.000432	CcSEcCtD
Paliperidone—Muscle spasms—Epirubicin—ovarian cancer	0.0003	0.000431	CcSEcCtD
Paliperidone—Immune system disorder—Doxorubicin—ovarian cancer	0.0003	0.00043	CcSEcCtD
Paliperidone—Mediastinal disorder—Doxorubicin—ovarian cancer	0.000299	0.000429	CcSEcCtD
Paliperidone—Body temperature increased—Docetaxel—ovarian cancer	0.000299	0.000428	CcSEcCtD
Paliperidone—Abdominal pain—Docetaxel—ovarian cancer	0.000299	0.000428	CcSEcCtD
Paliperidone—Chills—Doxorubicin—ovarian cancer	0.000298	0.000427	CcSEcCtD
Paliperidone—Dizziness—Paclitaxel—ovarian cancer	0.000295	0.000423	CcSEcCtD
Paliperidone—Vision blurred—Epirubicin—ovarian cancer	0.000294	0.000422	CcSEcCtD
Paliperidone—Alopecia—Doxorubicin—ovarian cancer	0.000293	0.000421	CcSEcCtD
Paliperidone—Mental disorder—Doxorubicin—ovarian cancer	0.000291	0.000417	CcSEcCtD
Paliperidone—Ill-defined disorder—Epirubicin—ovarian cancer	0.00029	0.000416	CcSEcCtD
Paliperidone—Erythema—Doxorubicin—ovarian cancer	0.000289	0.000414	CcSEcCtD
Paliperidone—Malnutrition—Doxorubicin—ovarian cancer	0.000289	0.000414	CcSEcCtD
Paliperidone—Anaemia—Epirubicin—ovarian cancer	0.000289	0.000414	CcSEcCtD
Paliperidone—Agitation—Epirubicin—ovarian cancer	0.000287	0.000412	CcSEcCtD
Paliperidone—Flatulence—Doxorubicin—ovarian cancer	0.000285	0.000408	CcSEcCtD
Paliperidone—Tension—Doxorubicin—ovarian cancer	0.000284	0.000407	CcSEcCtD
Paliperidone—Vomiting—Paclitaxel—ovarian cancer	0.000283	0.000407	CcSEcCtD
Paliperidone—Dysgeusia—Doxorubicin—ovarian cancer	0.000283	0.000406	CcSEcCtD
Paliperidone—Malaise—Epirubicin—ovarian cancer	0.000282	0.000404	CcSEcCtD
Paliperidone—Rash—Paclitaxel—ovarian cancer	0.000281	0.000403	CcSEcCtD
Paliperidone—Dermatitis—Paclitaxel—ovarian cancer	0.000281	0.000403	CcSEcCtD
Paliperidone—Nervousness—Doxorubicin—ovarian cancer	0.000281	0.000403	CcSEcCtD
Paliperidone—Vertigo—Epirubicin—ovarian cancer	0.000281	0.000402	CcSEcCtD
Paliperidone—Syncope—Epirubicin—ovarian cancer	0.00028	0.000402	CcSEcCtD
Paliperidone—Leukopenia—Epirubicin—ovarian cancer	0.00028	0.000401	CcSEcCtD
Paliperidone—Back pain—Doxorubicin—ovarian cancer	0.000279	0.000401	CcSEcCtD
Paliperidone—Headache—Paclitaxel—ovarian cancer	0.000279	0.000401	CcSEcCtD
Paliperidone—Hypersensitivity—Docetaxel—ovarian cancer	0.000278	0.000399	CcSEcCtD
Paliperidone—Muscle spasms—Doxorubicin—ovarian cancer	0.000278	0.000398	CcSEcCtD
Paliperidone—Palpitations—Epirubicin—ovarian cancer	0.000276	0.000396	CcSEcCtD
Paliperidone—Loss of consciousness—Epirubicin—ovarian cancer	0.000274	0.000394	CcSEcCtD
Paliperidone—Cough—Epirubicin—ovarian cancer	0.000272	0.000391	CcSEcCtD
Paliperidone—Vision blurred—Doxorubicin—ovarian cancer	0.000272	0.000391	CcSEcCtD
Paliperidone—Asthenia—Docetaxel—ovarian cancer	0.000271	0.000389	CcSEcCtD
Paliperidone—Convulsion—Epirubicin—ovarian cancer	0.000271	0.000388	CcSEcCtD
Paliperidone—Hypertension—Epirubicin—ovarian cancer	0.00027	0.000387	CcSEcCtD
Paliperidone—Ill-defined disorder—Doxorubicin—ovarian cancer	0.000268	0.000385	CcSEcCtD
Paliperidone—Pruritus—Docetaxel—ovarian cancer	0.000267	0.000383	CcSEcCtD
Paliperidone—Anaemia—Doxorubicin—ovarian cancer	0.000267	0.000383	CcSEcCtD
Paliperidone—Chest pain—Epirubicin—ovarian cancer	0.000266	0.000381	CcSEcCtD
Paliperidone—Arthralgia—Epirubicin—ovarian cancer	0.000266	0.000381	CcSEcCtD
Paliperidone—Myalgia—Epirubicin—ovarian cancer	0.000266	0.000381	CcSEcCtD
Paliperidone—Agitation—Doxorubicin—ovarian cancer	0.000266	0.000381	CcSEcCtD
Paliperidone—Anxiety—Epirubicin—ovarian cancer	0.000265	0.00038	CcSEcCtD
Paliperidone—Nausea—Paclitaxel—ovarian cancer	0.000265	0.00038	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—ovarian cancer	0.000264	0.000379	CcSEcCtD
Paliperidone—Discomfort—Epirubicin—ovarian cancer	0.000263	0.000377	CcSEcCtD
Paliperidone—Malaise—Doxorubicin—ovarian cancer	0.000261	0.000374	CcSEcCtD
Paliperidone—Dry mouth—Epirubicin—ovarian cancer	0.00026	0.000373	CcSEcCtD
Paliperidone—Vertigo—Doxorubicin—ovarian cancer	0.00026	0.000372	CcSEcCtD
Paliperidone—Syncope—Doxorubicin—ovarian cancer	0.000259	0.000372	CcSEcCtD
Paliperidone—Leukopenia—Doxorubicin—ovarian cancer	0.000259	0.000371	CcSEcCtD
Paliperidone—Diarrhoea—Docetaxel—ovarian cancer	0.000259	0.000371	CcSEcCtD
Paliperidone—Confusional state—Epirubicin—ovarian cancer	0.000257	0.000369	CcSEcCtD
Paliperidone—Palpitations—Doxorubicin—ovarian cancer	0.000255	0.000366	CcSEcCtD
Paliperidone—Oedema—Epirubicin—ovarian cancer	0.000255	0.000366	CcSEcCtD
Paliperidone—Anaphylactic shock—Epirubicin—ovarian cancer	0.000255	0.000366	CcSEcCtD
Paliperidone—Loss of consciousness—Doxorubicin—ovarian cancer	0.000254	0.000364	CcSEcCtD
Paliperidone—Infection—Epirubicin—ovarian cancer	0.000253	0.000363	CcSEcCtD
Paliperidone—Cough—Doxorubicin—ovarian cancer	0.000252	0.000362	CcSEcCtD
Paliperidone—Shock—Epirubicin—ovarian cancer	0.000251	0.00036	CcSEcCtD
Paliperidone—Convulsion—Doxorubicin—ovarian cancer	0.00025	0.000359	CcSEcCtD
Paliperidone—Nervous system disorder—Epirubicin—ovarian cancer	0.00025	0.000358	CcSEcCtD
Paliperidone—Dizziness—Docetaxel—ovarian cancer	0.00025	0.000358	CcSEcCtD
Paliperidone—Thrombocytopenia—Epirubicin—ovarian cancer	0.00025	0.000358	CcSEcCtD
Paliperidone—Hypertension—Doxorubicin—ovarian cancer	0.000249	0.000358	CcSEcCtD
Paliperidone—Tachycardia—Epirubicin—ovarian cancer	0.000249	0.000357	CcSEcCtD
Paliperidone—Skin disorder—Epirubicin—ovarian cancer	0.000248	0.000355	CcSEcCtD
Paliperidone—Arthralgia—Doxorubicin—ovarian cancer	0.000246	0.000353	CcSEcCtD
Paliperidone—Chest pain—Doxorubicin—ovarian cancer	0.000246	0.000353	CcSEcCtD
Paliperidone—Myalgia—Doxorubicin—ovarian cancer	0.000246	0.000353	CcSEcCtD
Paliperidone—Anxiety—Doxorubicin—ovarian cancer	0.000245	0.000352	CcSEcCtD
Paliperidone—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—ovarian cancer	0.000244	0.00035	CcSEcCtD
Paliperidone—Discomfort—Doxorubicin—ovarian cancer	0.000243	0.000349	CcSEcCtD
Paliperidone—Anorexia—Epirubicin—ovarian cancer	0.000243	0.000348	CcSEcCtD
Paliperidone—Dry mouth—Doxorubicin—ovarian cancer	0.000241	0.000345	CcSEcCtD
Paliperidone—Vomiting—Docetaxel—ovarian cancer	0.00024	0.000345	CcSEcCtD
Paliperidone—Rash—Docetaxel—ovarian cancer	0.000238	0.000342	CcSEcCtD
Paliperidone—Hypotension—Epirubicin—ovarian cancer	0.000238	0.000342	CcSEcCtD
Paliperidone—Dermatitis—Docetaxel—ovarian cancer	0.000238	0.000341	CcSEcCtD
Paliperidone—Confusional state—Doxorubicin—ovarian cancer	0.000238	0.000341	CcSEcCtD
Paliperidone—Headache—Docetaxel—ovarian cancer	0.000237	0.00034	CcSEcCtD
Paliperidone—Anaphylactic shock—Doxorubicin—ovarian cancer	0.000236	0.000338	CcSEcCtD
Paliperidone—Oedema—Doxorubicin—ovarian cancer	0.000236	0.000338	CcSEcCtD
Paliperidone—Infection—Doxorubicin—ovarian cancer	0.000234	0.000336	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Epirubicin—ovarian cancer	0.000232	0.000333	CcSEcCtD
Paliperidone—Shock—Doxorubicin—ovarian cancer	0.000232	0.000333	CcSEcCtD
Paliperidone—Nervous system disorder—Doxorubicin—ovarian cancer	0.000231	0.000332	CcSEcCtD
Paliperidone—Thrombocytopenia—Doxorubicin—ovarian cancer	0.000231	0.000331	CcSEcCtD
Paliperidone—Insomnia—Epirubicin—ovarian cancer	0.000231	0.000331	CcSEcCtD
Paliperidone—Tachycardia—Doxorubicin—ovarian cancer	0.00023	0.00033	CcSEcCtD
Paliperidone—Skin disorder—Doxorubicin—ovarian cancer	0.000229	0.000329	CcSEcCtD
Paliperidone—Paraesthesia—Epirubicin—ovarian cancer	0.000229	0.000328	CcSEcCtD
Paliperidone—Dyspnoea—Epirubicin—ovarian cancer	0.000227	0.000326	CcSEcCtD
Paliperidone—Somnolence—Epirubicin—ovarian cancer	0.000227	0.000325	CcSEcCtD
Paliperidone—Anorexia—Doxorubicin—ovarian cancer	0.000225	0.000322	CcSEcCtD
Paliperidone—Nausea—Docetaxel—ovarian cancer	0.000224	0.000322	CcSEcCtD
Paliperidone—Dyspepsia—Epirubicin—ovarian cancer	0.000224	0.000322	CcSEcCtD
Paliperidone—Decreased appetite—Epirubicin—ovarian cancer	0.000222	0.000318	CcSEcCtD
Paliperidone—Hypotension—Doxorubicin—ovarian cancer	0.00022	0.000316	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.00022	0.000316	CcSEcCtD
Paliperidone—Fatigue—Epirubicin—ovarian cancer	0.00022	0.000315	CcSEcCtD
Paliperidone—Pain—Epirubicin—ovarian cancer	0.000218	0.000313	CcSEcCtD
Paliperidone—Constipation—Epirubicin—ovarian cancer	0.000218	0.000313	CcSEcCtD
Paliperidone—Musculoskeletal discomfort—Doxorubicin—ovarian cancer	0.000215	0.000308	CcSEcCtD
Paliperidone—Insomnia—Doxorubicin—ovarian cancer	0.000213	0.000306	CcSEcCtD
Paliperidone—Paraesthesia—Doxorubicin—ovarian cancer	0.000212	0.000304	CcSEcCtD
Paliperidone—Dyspnoea—Doxorubicin—ovarian cancer	0.00021	0.000302	CcSEcCtD
Paliperidone—Feeling abnormal—Epirubicin—ovarian cancer	0.00021	0.000301	CcSEcCtD
Paliperidone—Somnolence—Doxorubicin—ovarian cancer	0.00021	0.000301	CcSEcCtD
Paliperidone—Gastrointestinal pain—Epirubicin—ovarian cancer	0.000208	0.000299	CcSEcCtD
Paliperidone—Dyspepsia—Doxorubicin—ovarian cancer	0.000208	0.000298	CcSEcCtD
Paliperidone—Decreased appetite—Doxorubicin—ovarian cancer	0.000205	0.000294	CcSEcCtD
Paliperidone—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.000204	0.000292	CcSEcCtD
Paliperidone—Fatigue—Doxorubicin—ovarian cancer	0.000203	0.000292	CcSEcCtD
Paliperidone—Urticaria—Epirubicin—ovarian cancer	0.000202	0.00029	CcSEcCtD
Paliperidone—Constipation—Doxorubicin—ovarian cancer	0.000202	0.000289	CcSEcCtD
Paliperidone—Pain—Doxorubicin—ovarian cancer	0.000202	0.000289	CcSEcCtD
Paliperidone—Body temperature increased—Epirubicin—ovarian cancer	0.000201	0.000289	CcSEcCtD
Paliperidone—Abdominal pain—Epirubicin—ovarian cancer	0.000201	0.000289	CcSEcCtD
Paliperidone—Feeling abnormal—Doxorubicin—ovarian cancer	0.000194	0.000279	CcSEcCtD
Paliperidone—Gastrointestinal pain—Doxorubicin—ovarian cancer	0.000193	0.000277	CcSEcCtD
Paliperidone—Hypersensitivity—Epirubicin—ovarian cancer	0.000188	0.000269	CcSEcCtD
Paliperidone—Urticaria—Doxorubicin—ovarian cancer	0.000187	0.000269	CcSEcCtD
Paliperidone—Abdominal pain—Doxorubicin—ovarian cancer	0.000186	0.000267	CcSEcCtD
Paliperidone—Body temperature increased—Doxorubicin—ovarian cancer	0.000186	0.000267	CcSEcCtD
Paliperidone—Asthenia—Epirubicin—ovarian cancer	0.000183	0.000262	CcSEcCtD
Paliperidone—Pruritus—Epirubicin—ovarian cancer	0.00018	0.000259	CcSEcCtD
Paliperidone—Diarrhoea—Epirubicin—ovarian cancer	0.000174	0.00025	CcSEcCtD
Paliperidone—Hypersensitivity—Doxorubicin—ovarian cancer	0.000174	0.000249	CcSEcCtD
Paliperidone—Asthenia—Doxorubicin—ovarian cancer	0.000169	0.000243	CcSEcCtD
Paliperidone—Dizziness—Epirubicin—ovarian cancer	0.000169	0.000242	CcSEcCtD
Paliperidone—Pruritus—Doxorubicin—ovarian cancer	0.000167	0.000239	CcSEcCtD
Paliperidone—Vomiting—Epirubicin—ovarian cancer	0.000162	0.000232	CcSEcCtD
Paliperidone—Diarrhoea—Doxorubicin—ovarian cancer	0.000161	0.000231	CcSEcCtD
Paliperidone—Rash—Epirubicin—ovarian cancer	0.000161	0.00023	CcSEcCtD
Paliperidone—Dermatitis—Epirubicin—ovarian cancer	0.000161	0.00023	CcSEcCtD
Paliperidone—Headache—Epirubicin—ovarian cancer	0.00016	0.000229	CcSEcCtD
Paliperidone—Dizziness—Doxorubicin—ovarian cancer	0.000156	0.000224	CcSEcCtD
Paliperidone—Nausea—Epirubicin—ovarian cancer	0.000151	0.000217	CcSEcCtD
Paliperidone—Vomiting—Doxorubicin—ovarian cancer	0.00015	0.000215	CcSEcCtD
Paliperidone—Rash—Doxorubicin—ovarian cancer	0.000149	0.000213	CcSEcCtD
Paliperidone—Dermatitis—Doxorubicin—ovarian cancer	0.000149	0.000213	CcSEcCtD
Paliperidone—Headache—Doxorubicin—ovarian cancer	0.000148	0.000212	CcSEcCtD
Paliperidone—Nausea—Doxorubicin—ovarian cancer	0.00014	0.000201	CcSEcCtD
Paliperidone—ADRA1B—Signaling Pathways—MMP9—ovarian cancer	1.84e-06	0.000159	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—HRAS—ovarian cancer	1.83e-06	0.000158	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—MYC—ovarian cancer	1.83e-06	0.000158	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CDKN1B—ovarian cancer	1.83e-06	0.000158	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—HRAS—ovarian cancer	1.83e-06	0.000158	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—PTEN—ovarian cancer	1.83e-06	0.000158	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—PIK3CA—ovarian cancer	1.82e-06	0.000157	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—MAPK1—ovarian cancer	1.82e-06	0.000157	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—EGFR—ovarian cancer	1.81e-06	0.000157	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling by GPCR—AKT1—ovarian cancer	1.81e-06	0.000156	CbGpPWpGaD
Paliperidone—DRD2—GPCR downstream signaling—AKT1—ovarian cancer	1.81e-06	0.000156	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CXCL8—ovarian cancer	1.81e-06	0.000156	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PTEN—ovarian cancer	1.8e-06	0.000156	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	1.8e-06	0.000156	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	1.8e-06	0.000155	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CDKN1B—ovarian cancer	1.8e-06	0.000155	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—VEGFA—ovarian cancer	1.8e-06	0.000155	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—HRAS—ovarian cancer	1.79e-06	0.000155	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CASP3—ovarian cancer	1.79e-06	0.000155	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IL2—ovarian cancer	1.79e-06	0.000155	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—MAPK1—ovarian cancer	1.79e-06	0.000155	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—EGFR—ovarian cancer	1.79e-06	0.000155	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	1.78e-06	0.000154	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—IL6—ovarian cancer	1.78e-06	0.000154	CbGpPWpGaD
Paliperidone—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	1.78e-06	0.000154	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—STAT3—ovarian cancer	1.78e-06	0.000154	CbGpPWpGaD
Paliperidone—HRH1—GPCR downstream signaling—AKT1—ovarian cancer	1.78e-06	0.000153	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—PIK3CA—ovarian cancer	1.78e-06	0.000153	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CG—ovarian cancer	1.78e-06	0.000153	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	1.77e-06	0.000153	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	1.77e-06	0.000153	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CASP3—ovarian cancer	1.77e-06	0.000152	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CDKN1B—ovarian cancer	1.76e-06	0.000152	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IL2—ovarian cancer	1.76e-06	0.000152	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CASP3—ovarian cancer	1.76e-06	0.000152	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IL2—ovarian cancer	1.76e-06	0.000152	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—TP53—ovarian cancer	1.76e-06	0.000152	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—IL6—ovarian cancer	1.75e-06	0.000151	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—IL6—ovarian cancer	1.75e-06	0.000151	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—PIK3CA—ovarian cancer	1.75e-06	0.000151	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CCND1—ovarian cancer	1.75e-06	0.000151	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	1.75e-06	0.000151	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	1.75e-06	0.000151	CbGpPWpGaD
Paliperidone—ADRA1A—GPCR downstream signaling—AKT1—ovarian cancer	1.74e-06	0.000151	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	1.73e-06	0.00015	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	1.73e-06	0.00015	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	1.73e-06	0.000149	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CASP3—ovarian cancer	1.73e-06	0.000149	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IL2—ovarian cancer	1.73e-06	0.000149	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	1.73e-06	0.000149	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—TP53—ovarian cancer	1.72e-06	0.000148	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CCND1—ovarian cancer	1.72e-06	0.000148	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—IL6—ovarian cancer	1.72e-06	0.000148	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—STAT3—ovarian cancer	1.72e-06	0.000148	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CCND1—ovarian cancer	1.71e-06	0.000148	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—KRAS—ovarian cancer	1.71e-06	0.000148	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—NRAS—ovarian cancer	1.71e-06	0.000148	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—STAT3—ovarian cancer	1.71e-06	0.000147	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—NRAS—ovarian cancer	1.7e-06	0.000147	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	1.7e-06	0.000147	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	1.7e-06	0.000147	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—CTNNB1—ovarian cancer	1.7e-06	0.000147	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MMP9—ovarian cancer	1.7e-06	0.000146	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—TP53—ovarian cancer	1.69e-06	0.000146	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—KRAS—ovarian cancer	1.69e-06	0.000146	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PTEN—ovarian cancer	1.69e-06	0.000145	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CCND1—ovarian cancer	1.68e-06	0.000145	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—HRAS—ovarian cancer	1.68e-06	0.000145	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	1.68e-06	0.000145	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	1.68e-06	0.000145	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MMP9—ovarian cancer	1.67e-06	0.000144	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	1.67e-06	0.000144	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—CTNNB1—ovarian cancer	1.67e-06	0.000144	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MMP9—ovarian cancer	1.66e-06	0.000144	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	1.66e-06	0.000143	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PTEN—ovarian cancer	1.66e-06	0.000143	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	1.66e-06	0.000143	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PTEN—ovarian cancer	1.66e-06	0.000143	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PTEN—ovarian cancer	1.65e-06	0.000143	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MYC—ovarian cancer	1.65e-06	0.000143	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	1.65e-06	0.000143	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—HRAS—ovarian cancer	1.65e-06	0.000142	CbGpPWpGaD
Paliperidone—DRD2—Signaling by GPCR—AKT1—ovarian cancer	1.64e-06	0.000142	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	1.64e-06	0.000142	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	1.64e-06	0.000141	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	1.64e-06	0.000141	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MMP9—ovarian cancer	1.63e-06	0.000141	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	1.63e-06	0.000141	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	1.63e-06	0.000141	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PTEN—ovarian cancer	1.62e-06	0.00014	CbGpPWpGaD
Paliperidone—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	1.62e-06	0.00014	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—HRAS—ovarian cancer	1.62e-06	0.00014	CbGpPWpGaD
Paliperidone—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	1.62e-06	0.00014	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	1.62e-06	0.00014	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	1.62e-06	0.00014	CbGpPWpGaD
Paliperidone—HRH1—Signaling by GPCR—AKT1—ovarian cancer	1.61e-06	0.000139	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—ABCB1—ovarian cancer	1.61e-06	0.000139	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—IL6—ovarian cancer	1.61e-06	0.000139	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	1.61e-06	0.000139	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IL2—ovarian cancer	1.6e-06	0.000138	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	1.6e-06	0.000138	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MYC—ovarian cancer	1.6e-06	0.000138	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	1.59e-06	0.000137	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MYC—ovarian cancer	1.59e-06	0.000137	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling by GPCR—AKT1—ovarian cancer	1.58e-06	0.000137	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—TYMS—ovarian cancer	1.58e-06	0.000137	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—PIK3CA—ovarian cancer	1.58e-06	0.000136	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—IL6—ovarian cancer	1.57e-06	0.000136	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—PIK3CA—ovarian cancer	1.57e-06	0.000135	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	1.56e-06	0.000135	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	1.56e-06	0.000135	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CD—ovarian cancer	1.56e-06	0.000135	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	1.56e-06	0.000135	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—EGFR—ovarian cancer	1.56e-06	0.000135	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—PIK3CA—ovarian cancer	1.55e-06	0.000134	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	1.55e-06	0.000134	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—EGFR—ovarian cancer	1.55e-06	0.000134	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—IL6—ovarian cancer	1.55e-06	0.000134	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	1.55e-06	0.000134	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MYC—ovarian cancer	1.54e-06	0.000133	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	1.53e-06	0.000132	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—TP53—ovarian cancer	1.52e-06	0.000132	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—VEGFA—ovarian cancer	1.52e-06	0.000131	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MYC—ovarian cancer	1.52e-06	0.000131	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	1.52e-06	0.000131	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	1.51e-06	0.00013	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	1.51e-06	0.00013	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	1.51e-06	0.00013	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—STAT3—ovarian cancer	1.51e-06	0.00013	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—NRAS—ovarian cancer	1.5e-06	0.00013	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—TP53—ovarian cancer	1.5e-06	0.00013	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	1.5e-06	0.000129	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—VEGFA—ovarian cancer	1.49e-06	0.000129	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	1.49e-06	0.000128	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	1.49e-06	0.000128	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—STAT3—ovarian cancer	1.48e-06	0.000128	CbGpPWpGaD
Paliperidone—HTR1D—Signaling Pathways—AKT1—ovarian cancer	1.48e-06	0.000128	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—STAT3—ovarian cancer	1.48e-06	0.000128	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—NRAS—ovarian cancer	1.48e-06	0.000128	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—NRAS—ovarian cancer	1.48e-06	0.000127	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—KRAS—ovarian cancer	1.47e-06	0.000127	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	1.47e-06	0.000127	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—VEGFA—ovarian cancer	1.47e-06	0.000127	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—KRAS—ovarian cancer	1.47e-06	0.000127	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—HRAS—ovarian cancer	1.46e-06	0.000126	CbGpPWpGaD
Paliperidone—HTR1B—Signaling Pathways—AKT1—ovarian cancer	1.45e-06	0.000125	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—STAT3—ovarian cancer	1.45e-06	0.000125	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—NRAS—ovarian cancer	1.45e-06	0.000125	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MAPK3—ovarian cancer	1.44e-06	0.000124	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—HRAS—ovarian cancer	1.44e-06	0.000124	CbGpPWpGaD
Paliperidone—DRD4—Signaling Pathways—AKT1—ovarian cancer	1.43e-06	0.000123	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	1.43e-06	0.000123	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	1.42e-06	0.000122	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MAPK3—ovarian cancer	1.41e-06	0.000122	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	1.4e-06	0.000121	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	1.4e-06	0.000121	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MYC—ovarian cancer	1.4e-06	0.000121	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—IL6—ovarian cancer	1.39e-06	0.00012	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MAPK3—ovarian cancer	1.39e-06	0.00012	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MYC—ovarian cancer	1.38e-06	0.000119	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—IL6—ovarian cancer	1.38e-06	0.000119	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MYC—ovarian cancer	1.38e-06	0.000119	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—MAPK1—ovarian cancer	1.37e-06	0.000118	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—EGFR—ovarian cancer	1.37e-06	0.000118	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	1.36e-06	0.000118	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CB—ovarian cancer	1.36e-06	0.000117	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—TP53—ovarian cancer	1.36e-06	0.000117	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	1.35e-06	0.000117	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MYC—ovarian cancer	1.35e-06	0.000116	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	1.35e-06	0.000116	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	1.35e-06	0.000116	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—EGFR—ovarian cancer	1.35e-06	0.000116	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	1.35e-06	0.000116	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	1.35e-06	0.000116	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—MAPK1—ovarian cancer	1.35e-06	0.000116	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—EGFR—ovarian cancer	1.35e-06	0.000116	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—MAPK1—ovarian cancer	1.32e-06	0.000114	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—EGFR—ovarian cancer	1.32e-06	0.000114	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	1.31e-06	0.000113	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—TP53—ovarian cancer	1.31e-06	0.000113	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—TP53—ovarian cancer	1.3e-06	0.000113	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	1.3e-06	0.000112	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—KRAS—ovarian cancer	1.29e-06	0.000112	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	1.29e-06	0.000111	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	1.29e-06	0.000111	CbGpPWpGaD
Paliperidone—DRD1—Signaling Pathways—AKT1—ovarian cancer	1.29e-06	0.000111	CbGpPWpGaD
Paliperidone—ADRA2C—Metabolism—AKT1—ovarian cancer	1.28e-06	0.000111	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—CAV1—ovarian cancer	1.27e-06	0.00011	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—KRAS—ovarian cancer	1.27e-06	0.00011	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—PIK3CA—ovarian cancer	1.27e-06	0.00011	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—KRAS—ovarian cancer	1.27e-06	0.00011	CbGpPWpGaD
Paliperidone—DRD3—Signaling Pathways—AKT1—ovarian cancer	1.27e-06	0.00011	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—TP53—ovarian cancer	1.27e-06	0.000109	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MYC—ovarian cancer	1.25e-06	0.000108	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—HRAS—ovarian cancer	1.25e-06	0.000108	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—TP53—ovarian cancer	1.25e-06	0.000108	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—KRAS—ovarian cancer	1.25e-06	0.000108	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—HRAS—ovarian cancer	1.25e-06	0.000108	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—IL6—ovarian cancer	1.24e-06	0.000107	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	1.23e-06	0.000106	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	1.23e-06	0.000106	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	1.21e-06	0.000105	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—IL6—ovarian cancer	1.2e-06	0.000104	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	1.19e-06	0.000103	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—IL6—ovarian cancer	1.19e-06	0.000103	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	1.19e-06	0.000103	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PTEN—ovarian cancer	1.18e-06	0.000101	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	1.17e-06	0.000101	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—PIK3CA—ovarian cancer	1.17e-06	0.000101	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—PIK3CA—ovarian cancer	1.17e-06	0.000101	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CG—ovarian cancer	1.16e-06	0.0001	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—IL6—ovarian cancer	1.16e-06	0.0001	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	1.16e-06	0.0001	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—TP53—ovarian cancer	1.15e-06	9.93e-05	CbGpPWpGaD
Paliperidone—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	1.15e-06	9.89e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—PIK3CA—ovarian cancer	1.15e-06	9.89e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—IL6—ovarian cancer	1.14e-06	9.86e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—TP53—ovarian cancer	1.13e-06	9.77e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—TP53—ovarian cancer	1.13e-06	9.75e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—TP53—ovarian cancer	1.11e-06	9.57e-05	CbGpPWpGaD
Paliperidone—HTR1A—Signaling Pathways—AKT1—ovarian cancer	1.11e-06	9.55e-05	CbGpPWpGaD
Paliperidone—HTR2C—Signaling Pathways—AKT1—ovarian cancer	1.1e-06	9.5e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—HRAS—ovarian cancer	1.1e-06	9.5e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—HRAS—ovarian cancer	1.08e-06	9.34e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—HRAS—ovarian cancer	1.08e-06	9.32e-05	CbGpPWpGaD
Paliperidone—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	1.07e-06	9.24e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	1.06e-06	9.19e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—HRAS—ovarian cancer	1.06e-06	9.15e-05	CbGpPWpGaD
Paliperidone—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	1.05e-06	9.09e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—IL6—ovarian cancer	1.05e-06	9.09e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Metabolism—AKT1—ovarian cancer	1.04e-06	8.98e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—IL6—ovarian cancer	1.04e-06	8.94e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—IL6—ovarian cancer	1.03e-06	8.92e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—TP53—ovarian cancer	1.03e-06	8.89e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CD—ovarian cancer	1.02e-06	8.81e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—IL6—ovarian cancer	1.01e-06	8.76e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	9.85e-07	8.5e-05	CbGpPWpGaD
Paliperidone—DRD2—Signaling Pathways—AKT1—ovarian cancer	9.72e-07	8.38e-05	CbGpPWpGaD
Paliperidone—HTR2A—Signaling Pathways—AKT1—ovarian cancer	9.56e-07	8.25e-05	CbGpPWpGaD
Paliperidone—HRH1—Signaling Pathways—AKT1—ovarian cancer	9.54e-07	8.23e-05	CbGpPWpGaD
Paliperidone—CYP3A5—Metabolism—AKT1—ovarian cancer	9.53e-07	8.23e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—IL6—ovarian cancer	9.43e-07	8.14e-05	CbGpPWpGaD
Paliperidone—ADRA1A—Signaling Pathways—AKT1—ovarian cancer	9.36e-07	8.08e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CB—ovarian cancer	8.9e-07	7.68e-05	CbGpPWpGaD
Paliperidone—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	8.7e-07	7.51e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—PIK3CA—ovarian cancer	8.3e-07	7.16e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PTEN—ovarian cancer	7.69e-07	6.64e-05	CbGpPWpGaD
Paliperidone—CYP2D6—Metabolism—AKT1—ovarian cancer	6.78e-07	5.85e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—PIK3CA—ovarian cancer	5.42e-07	4.68e-05	CbGpPWpGaD
Paliperidone—CYP3A4—Metabolism—AKT1—ovarian cancer	4.43e-07	3.82e-05	CbGpPWpGaD
